Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients

Journal of Immunology Research

Volumn 2015, Issue , 2015, Pages

  Yutani, Shigeru ^a   Ueshima, Kazuomi ^b   Abe, Kazumichi ^c   Ishiguro, Atsushi ^d   Eguchi, Junichi ^e   Matsueda, Satoko ^a   Komatsu, Nobukazu ^f   Shichijo, Shigeki ^a   Yamada, Akira ^a   Itoh, Kyogo ^a   Sasada, Tetsuro ^a,f   Kudo, Masatoshi ^b   Noguchi, Masanori ^a  

^a KURUME UNIVERSITY   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^d HIROSAKI UNIVERSITY   (Japan)

^e SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IMMUNOGLOBULIN G; MONTANIDE ISA 51; PEPTIDE VACCINE; SORAFENIB; TUMOR ANTIGEN; CANCER VACCINE; SUBUNIT VACCINE; VIRUS ANTIGEN;

ABDOMINAL DISTENSION; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANTIBODY RESPONSE; ARTICLE; ASCITES; CLINICAL ARTICLE; CONSTIPATION; CYTOTOXIC T LYMPHOCYTE; DRUG SAFETY; FEMALE; FEVER; HEPATITIS C VIRUS; HUMAN; HYPERTENSION; IMMUNE RESPONSE; INJECTION SITE REACTION; INSOMNIA; LEUKOPENIA; LIVER CELL CARCINOMA; LYMPHOCYTOPENIA; MALAISE; MALE; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PERIPHERAL EDEMA; PERSONALIZED PEPTIDE VACCINATION; PHASE 2 CLINICAL TRIAL; PLEURISY; PRURITUS; SIDE EFFECT; THROMBOCYTOPENIA; URINE INCONTINENCE; VACCINATION; BLOOD; CARCINOMA, HEPATOCELLULAR; CHEMISTRY; CLINICAL TRIAL; HEPACIVIRUS; HEPATITIS C; IMMUNIZATION; IMMUNOLOGY; LIVER NEOPLASMS; MIDDLE AGED; PERSONALIZED MEDICINE; SURVIVAL ANALYSIS; VIROLOGY; YOUNG ADULT;

ADULT; AGED; ANTIGENS, NEOPLASM; ANTIGENS, VIRAL; CANCER VACCINES; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNIZATION SCHEDULE; IMMUNOGLOBULIN G; LIVER NEOPLASMS; MALE; MIDDLE AGED; PRECISION MEDICINE; SURVIVAL ANALYSIS; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, SUBUNIT; YOUNG ADULT;

EID: 84946070010     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2015/473909     Document Type: Article

References (24)

1. J. M. Llovet, S. Ricci, V. Mazzaferro et al., "Sorafenib in advanced hepatocellular carcinoma, " The New England Journal of Medicine, vol. 359, no. 4, pp. 378-390, 2008.
2. A.-L. Cheng, Y.-K. Kang, Z. Chen et al., "Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, doubleblind, placebo-controlled trial, "TheLancetOncology, vol. 10, no. 1, pp. 25-34, 2009.
3. A.-L. Cheng, Y.-K. Kang, D.-Y. Lin et al., "Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial, " Journal of Clinical Oncology, vol. 31, no. 32, pp. 4067-4075, 2013.
4. J. M. Llovet, T. Decaens, J.-L. Raoul et al., "Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study, " Journal of Clinical Oncology, vol. 31, no. 28, pp. 3509-3516, 2013.
5. T. F. Greten, A. G. Duffy, and F. Korangy, "Hepatocellular carcinoma from an immunologic perspective, " Clinical Cancer Research, vol. 19, no. 24, pp. 6678-6685, 2013.
6. J. Heo, T. Reid, L. Ruo et al., "Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer, " Nature Medicine, vol. 19, no. 3, pp. 329-336, 2013.
7. B.-H. Park, T. Hwang, T.-C. Liu et al., "Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: A phase I trial, " The Lancet Oncology, vol. 9, no. 6, pp. 533-542, 2008.
8. Y. Sawada, T. Yoshikawa, D. Nobuoka et al., "Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival, " Clinical Cancer Research, vol. 18, no. 13, pp. 3686-3696, 2012.
9. B. Sangro, C. Gomez-Martin, M. de la Mata et al., "A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C, " Journal of Hepatology, vol. 59, no. 1, pp. 81-88, 2013.
10. M. Terasaki, S. Shibui, Y. Narita et al., "Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen-A24 with recurrent or progressive glioblastoma multiforme, " Journal of Clinical Oncology, vol. 29, no. 3, pp. 337-344, 2011.
11. R. Takahashi, Y. Ishibashi, K. Hiraoka et al., "Phase II study of personalized peptide vaccination for refractory bone and soft tissue sarcoma patients, " Cancer Science, vol. 104, no. 10, pp. 1285-1294, 2013.
12. M. Noguchi, T. Kakuma, H. Uemura et al., "A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer, " Cancer Immunology, Immunotherapy, vol. 59, no. 7, pp. 1001-1009, 2010.
13. M. Noguchi, T. Sasada, and K. Itoh, "Personalized peptide vaccination: A new approach for advanced cancer as therapeutic cancer vaccine, " Cancer Immunology, Immunotherapy, vol. 62, no. 5, pp. 919-929, 2013.
14. K. Matsumoto, M. Noguchi, T. Satoh et al., "A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin, " BJU International, vol. 108, no. 6, pp. 831-838, 2011.
15. K. Yoshida, M. Noguchi, T. Mine et al., "Characteristics of severe adverse events after peptide vaccination for advanced cancer patients: Analysis of 500 cases, " Oncology Reports, vol. 25, no. 1, pp. 57-62, 2011.
16. N. Komatsu, S. Yutani, A. Yamada et al., "Prophylactic effect of peptide vaccination against hepatocellular carcinoma associated with hepatitis C virus, " Experimental and Therapeutic Medicine, vol. 1, no. 4, pp. 619-626, 2010.
17. S. Yutani, A. Yamada, K. Yoshida et al., "Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1bwho failed to respond to interferonbased therapy, " Vaccine, vol. 25, no. 42, pp. 7429-7435, 2007.
18. S. Yutani, N. Komatsu, S. Shichijo et al., "Phase I clinical study of a peptide vaccination for hepatitis C virus-infected patients with different human leukocyte antigen-class I-A alleles, " Cancer Science, vol. 100, no. 10, pp. 1935-1942, 2009.
19. Y. Niu, N. Komatsu, Y. Komohara et al., "A peptide derived from hepatitisCvirus (HCV) core protein inducing cellularresponses in patients withHCVwith various HLA class IA alleles, " Journal of Medical Virology, vol. 81, no. 7, pp. 1232-1240, 2009.
20. M. Kudo, H. Chung, S. Haji et al., "Validation of a new prognostic staging system for hepatocellular carcinoma: The JIS score compared with the CLIP score, " Hepatology, vol. 40, no. 6, pp. 1396-1405, 2004.
21. M. Winkel od, D. Nagel, J. Sappl et al., "Prognosis of patients with hepatocellular carcinoma. Validation and ranking of established staging-systems in a large western HCC-cohort, " PLoS ONE, vol. 7, no. 10, Article IDe45066, 13 pages, 2012.
22. S. M. Rushbrook, S. M. Ward, E. Unitt et al., "Regulatory T cells suppress in vitro proliferation of virus-specific CD8+ T cells during persistent hepatitis C virus infection, " Journal of Virology, vol. 79, no. 12, pp. 7852-7859, 2005.
23. B. Platzer, M. Stout, and E. Fiebiger, "Antigen cross-presentation of immune complexes, " Frontiers in Immunology, vol. 5, article 140, 2014.
24. M. Noguchi, T. Mine, N. Komatsu et al., "Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination, " Cancer Biology andTherapy, vol. 10, no. 12, pp. 1266-1279, 2010.